Paul R. Helft, MD, discusses the incidence of gastrointestinal neuroendocrine tumors and available and emerging treatment methods.
Tanios Bekaii-Saab, MD, sheds light on the recent advances in the treatment of patients with hepatocellular carcinoma.
Adding the IDO1 inhibitor epacadostat to the PD-L1 inhibitor durvalumab (Imfinzi) failed to induce any clinical responses in patients with pancreatic cancer.
Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.
R. Kate Kelley, MD, discusses the incidence of and risk factors for HCC, and emphasizes the sequence of clinical trials that characterized the field in 2017.
Margaret A. Tempero, MD, discusseds frontline treatment options in pancreatic cancer and emphasized the use and difficulties of conventional and incoming therapies across disease states.
Zev A. Wainberg, MD, discusses data from the pancreatic cancer cohort of a trial evaluating cabiralizumab in combination with nivolumab.
Ramucirumab extended overall survival versus placebo as a second-line treatment for patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein, according to findings from the phase III REACH-2 trial.
Tanios Bekaii-Saab, MD, discusses emerging treatments offering hope to patients with pancreatic cancer.
Bert H. O’Neil, MD, discusses the role of molecular testing throughout GI cancers and highlights the current and developing treatment landscape for patients with colorectal cancer.